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Letter: immune checkpoint inhibitor‐induced colitis—shouldn't 
we be checking more often? Authors’ reply
We thank Dr. Samaan et al for their thoughtful letter regarding our 
recent paper.1,2 They raise several excellent points regarding the role 
and use of endoscopy in the evaluation of patients with suspected 
immune checkpoint inhibitor‐induced colitis.
We agree that endoscopy currently appears to be under‐utilised 
in the work‐up of this condition. Recent studies have shown that pa‐
tients with high‐risk endoscopic features were more likely to require 
biologic therapy.3,4 Thus, important prognostic as well as diagnostic 
information (e.g. excluding CMV infection and other processes) may 
be obtained by endoscopy.
Given the urgency of treating patients with severe presenta‐
tions of this condition, we suspect that oncologists may perceive 
endoscopy as a barrier that could delay timely initiation of treatment. 
We fully agree that closer relationships between gastroenterologists 
and oncologists including an “oncology liaison gastroenterologist” 
will probably allow for streamlined care. One of the authors (MSP) 
currently serves such a role with a well‐known National Cancer 
Institute‐designated cancer center in the metropolitan Detroit area. 
Strengthening these relationships will allow for more prospective 
studies to be performed to evaluate the role of endoscopy and non‐
invasive markers in evaluating this and other conditions with overlap 
between specialties.
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